Innate Pharma Stock

Innate Pharma EBIT

The EBIT of Innate Pharma (IPH.PA) as of Jul 28, 2026 is -53.43 M EUR. In the previous year, EBIT was -51.58 M EUR — a change of 3.59% (lower).

EBIT

-53.43 MEUR

YoY

3.59%

Last updated:

In 2026, Innate Pharma's EBIT was -53.43 M EUR, a 3.59% increase from the -51.58 M EUR EBIT recorded in the previous year.

The Innate Pharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2023
-12.67 base
Jan 1, 2024
-51.58 base
Jan 1, 2025
-53.43 base
Jan 1, 2026 (e)
22.38 base
Jan 1, 2027 (e)
-28.83 base
Jan 1, 2028 (e)
-65.42 base
Jan 1, 2029 (e)
41.24 base
Jan 1, 2030 (e)
64.20 base
YEAREBIT (M EUR)
2030 est 64.20
2029 est 41.24
2028 est -65.42
2027 est -28.83
2026 est 22.38
2025 -53.43
2024 -51.58
2023 -12.67
2022 -57.68
2021 -47.83
2020 1.08
2019 -27.05
2018 5.15
2017 -47.84
2016 7.57
2015 -10.77
2014 -19.97
2013 -2.79
2012 -3.39
2011 -7.57
2010 -13.69
2009 -15.54
2008 -11.01
2007 -9.09
2006 -7.24
Access this data via the Eulerpool API

Innate Pharma Revenue

Innate Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
51.90 M EUR
-12.67 M EUR
-7.57 M EUR
Jan 1, 2024
12.62 M EUR
-51.58 M EUR
-49.47 M EUR
Jan 1, 2025
2.79 M EUR
-53.43 M EUR
-49.18 M EUR
Jan 1, 2026 (e)
31.21 M EUR
22.38 M EUR
77.00 M EUR
Jan 1, 2027 (e)
64.75 M EUR
-28.83 M EUR
174.26 M EUR
Jan 1, 2028 (e)
80.73 M EUR
-65.42 M EUR
0.00 EUR
Jan 1, 2029 (e)
199.83 M EUR
41.24 M EUR
0.00 EUR
Jan 1, 2030 (e)
255.40 M EUR
64.20 M EUR
0.00 EUR

Innate Pharma Margins

Innate Pharma stock margins

The Innate Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innate Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innate Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
10.83 %
-24.41 %
-14.59 %
Jan 1, 2024
100.00 %
-408.64 %
-391.97 %
Jan 1, 2025
100.00 %
-1,916.94 %
-1,764.51 %
Jan 1, 2026 (e)
100.00 %
71.70 %
246.68 %
Jan 1, 2027 (e)
100.00 %
-44.53 %
269.14 %
Jan 1, 2028 (e)
100.00 %
-81.04 %
0.00 %
Jan 1, 2029 (e)
100.00 %
20.64 %
0.00 %
Jan 1, 2030 (e)
100.00 %
25.14 %
0.00 %

Innate Pharma Stock analysis

What does Innate Pharma do? The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Innate Pharma's EBIT

Innate Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Innate Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Innate Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Innate Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Innate Pharma stock

EBIT of Innate Pharma is -53.43 M EUR in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Innate Pharma

All Key Metrics — Innate Pharma